Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma
Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years. Results suggest...
Hemogenyx Pharmaceuticals PLC – Issue of Equity